Intellectual Disability Clinical Trial
— DEFIDIAGOfficial title:
Etude Pilote Des différentes stratégies de séquençage Haut débit du génome Pour le Diagnostic génétique Des Patients Atteints de déficience Intellectuelle
Verified date | March 2024 |
Source | Institut National de la Santé Et de la Recherche Médicale, France |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Introduction : Intellectual Disability (ID) is the most common cause of referral in the pediatric genetic centers and is characterized by an extreme genetic heterogeneity corresponding to a myriad of rare diseases that complicates the identification of ID's. Overall today in France, for non-syndromic ID affected patients, the Fra-X detection, the chromosomal microarray analysis and Gene Panel Strategy of 44 ID selected genes leads to a global diagnostic yield for 1/3 patients leaving 2/3 of patients still with no diagnosis. The advent, and burst, of Next Generation Sequencing (NGS) technologies has clearly revolutionized the approaches to diagnosis and research in the field of rare diseases at an international. That's why the main hypothesis of DEFIDIAG is that Whole Genome Sequencing (WGS) could allow to improve the diagnostic performance and cost-effectiveness for French patients with ID. Objective : The main objective of this study is to compare ther percentage of genetic causal diagnosis identified in ID patients by performing trio WGS analysis vs the use of the current French reference strategy (ACPA, X-Fra, DI 44). Methods and design : This is a prospective study. The investigators expect to include 1275 index case with his/her 2 biological unaffected parents.
Status | Active, not recruiting |
Enrollment | 3825 |
Est. completion date | December 2024 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | 1. Inclusion criteria for children or adults with ID of unknown etiology (index case) In order to be eligible to participate in this study, an individual must meet all the following criteria: - Age: 1. Between 0 and 5 years with stringent criteria (severe delayed development in terms of motor skills, language, and/or sociability) OR 2. = 6 years: patients with ID, whatever the severity (but with proven ID by ad hoc neuropsychological testing) and the associated manifestations - Without any obvious diagnosis identified during a genetic consultation in one of the participating center (i.e., an obvious syndrome with ID with well-known molecular diagnosis is excluded); - Provision of signed and dated of "participant" consent form; - Stated willingness to comply with all study procedures and availability for the duration of the study. Patient with a social security in compliance with the French law (Provisions relating to research involving the human person provided for in Articles L 1121-1 et seq. of the French Public Health Code). 2. Inclusion criteria for biological parents - Provision of signed and dated of both parents consent form. 3. Non-inclusion criteria - An individual, who presents any condition which in the investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol, will not be eligible; - Patients with isolated learning disabilities; - One or both parents with ID; - Parent placed under judicial protection (tutelle, curatelle et sauvegarde de justice) ; - Patient with a known etiological diagnosis (non-genetic, previously proven Fra-X syndrome, know chromosomal anomaly, known pathogenic or probably pathogenic variant identified in an ID gene by any technique). - For patient concerning by biobank project: hypersensitivity to local anesthesia |
Country | Name | City | State |
---|---|---|---|
France | CHU d'Angers | Angers | |
France | CHU Bordeaux | Bordeaux | |
France | Hospices Civil de Lyon | Bron | |
France | CHU Dijon | Dijon | |
France | CHU de Grenoble-Alpes | La Tronche | |
France | CHRU Lille | Lille | |
France | Assistance publique - Hôpitaux de Marseille | Marseille | |
France | CHU Montpellier | Montpellier | |
France | CHU Nantes | Nantes | |
France | Assistance publique - Hôpitaux de Paris - Groupe Hospitalier Pitié Salpétrière | Paris | |
France | Assistance publique - Hôpitaux de Paris - Hôpital Necker - Enfants malades | Paris | |
France | CHU Rennes | Rennes | |
France | CHU Rouen | Rouen | |
France | CHU Strasbourg | Strasbourg |
Lead Sponsor | Collaborator |
---|---|
Institut National de la Santé Et de la Recherche Médicale, France | APHP, Centre Hospitalier Universitaire Dijon, Commissariat A L'energie Atomique, Hospices Civils de Lyon, University Hospital, Rouen, University Hospital, Strasbourg |
France,
Binquet C, Lejeune C, Faivre L, Bouctot M, Asensio ML, Simon A, Deleuze JF, Boland A, Guillemin F, Seror V, Delmas C, Esperou H, Duffourd Y, Lyonnet S, Odent S, Heron D, Sanlaville D, Frebourg T, Gerard B, Dollfus H. Genome Sequencing for Genetics Diagnosis of Patients With Intellectual Disability: The DEFIDIAG Study. Front Genet. 2022 Feb 1;12:766964. doi: 10.3389/fgene.2021.766964. eCollection 2021. — View Citation
Lejeune C, Robert-Viard C, Meunier-Beillard N, Borel MA, Gourves L, Staraci S, Soilly AL, Guillemin F, Seror V, Achit H, Bouctot M, Asensio ML, Briffaut AS, Delmas C, Bruel AL, Benoit A, Simon A, Gerard B, Hadj Abdallah H, Lyonnet S, Faivre L, Thauvin-Robinet C, Odent S, Heron D, Sanlaville D, Frebourg T, Muller J, Duffourd Y, Boland A, Deleuze JF, Esperou H, Binquet C, Dollfus H. The Economic, Medical and Psychosocial Consequences of Whole Genome Sequencing for the Genetic Diagnosis of Patients With Intellectual Disability: The DEFIDIAG Study Protocol. Front Genet. 2022 Apr 4;13:852472. doi: 10.3389/fgene.2022.852472. eCollection 2022. — View Citation
Meuwissen M, Verstraeten A, Ranza E, Iwaszkiewicz J, Bastiaansen M, Mateiu L, Nemegeer M, Meester JAN, Afenjar A, Amaral M, Ballhausen D, Barnett S, Barth M, Asselbergh B, Spaas K, Heeman B, Bassetti J, Blackburn P, Schaer M, Blanc X, Zoete V, Casas K, Courtin T, Doummar D, Guerry F, Keren B, Pappas J, Rabin R, Begtrup A, Shinawi M, Vulto-van Silfhout AT, Kleefstra T, Wagner M, Ziegler A, Schaefer E, Gerard B, De Bie CI, Holwerda SJB, Abbot MA, Antonarakis SE, Loeys B. Heterozygous variants in CTR9, which encodes a major component of the PAF1 complex, are associated with a neurodevelopmental disorder. Genet Med. 2022 Jul;24(7):1583-1591. doi: 10.1016/j.gim.2022.04.003. Epub 2022 May 2. — View Citation
Ravindran E, Lesca G, Januel L, Goldgruber L, Dickmanns A, Margot H, Kaindl AM. Case report: Compound heterozygous NUP85 variants cause autosomal recessive primary microcephaly. Front Neurol. 2023 Feb 9;14:1124886. doi: 10.3389/fneur.2023.1124886. eCollection 2023. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Diagnostic Yield | The primary study endpoint is the identification of a causal diagnosis of ID defined as the identification of one class 4 or 5 variant (or two in case of autosomal recessive inheritance) that explains the symptoms presented by the patient. In addition variants classified as 3+, anticipated to become future 4 will be recorded. Specific analysis and follow up of the variant classified as 3+ (i.e. with a high probability of pathogenicity) will be done after the end of the protocol to determine the class 3+ to class 4-5 switch proportion and to describe the new genes/mechanisms involved in ID and revealed by DEFIDIAG. | 12 months | |
Secondary | Causal structural change | Identification of causal structural changes (CNV, translocation, inversion) in the first investigation population (confirmed during the MDM for the WGS strategies)
The clinical characteristics of patients and the diagnostic yield at each step of the incremental selection within WGS analyses (44GPS, OMIMOME, WES, WGS) according to the results of the preceding step as well as according to the results of chromosomal microarray analysis and 44GPS will also be parameters of interest in the whole population. |
12 months | |
Secondary | Incremental cost-effectiveness ratio | The cost-effectiveness endpoint will be an efficiency criterion based on the estimation of an incremental cost-effectiveness ratio, expressed in terms of cost per additional positive diagnosis. | 24 months | |
Secondary | Mean cost of wavering diagnostic research | Estimation of the cost of wavering diagnostic research | 24 months | |
Secondary | Percentage of at least one modification in medical, medico-social, rehabilitative and psychological follow-up | 24 months | ||
Secondary | Number and type of secondary data | The number and type of SFs (class 4 or 5 mutation(s)) identified in the parents that specifically consent to this study will be recorded in a specific report. The outcome will be defined by the percentage of SFs in the studied population and the number and type of medical consequences following their identification. | 12 months | |
Secondary | Median time and type of skills required for analyzing genetic data and for genetic confirmation | 12 months | ||
Secondary | Median time to obtain results | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05935722 -
Evaluation of a Home-based Parenting Support Program: Parenting Young Children
|
N/A | |
Completed |
NCT04020302 -
Self-Monitoring Shopping Intervention
|
N/A | |
Active, not recruiting |
NCT03548779 -
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
|
N/A | |
Completed |
NCT03722212 -
Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test
|
N/A | |
Not yet recruiting |
NCT03644797 -
Second Molecular Event Identification by Exome Sequencing for Intellectually Disabled Patients Carrying 16p13.11 CNVs
|
||
Completed |
NCT03139760 -
POWERSforID: A Telehealth Weight Management System for Adults With Intellectual Disability
|
N/A | |
Not yet recruiting |
NCT02881333 -
Various Type of Genetic Events in Patients With Intellectual Disability
|
N/A | |
Completed |
NCT02746614 -
Psychomotor Therapy Effects in Adaptive Behavior and Motor Proficiency in Intellectual Disability
|
N/A | |
Completed |
NCT06097819 -
Therapy-Based Games' Effects on Motor and Cognitive Skills in Intellectual Disabilities
|
N/A | |
Recruiting |
NCT05767203 -
Genetic Markers and Biomarkers in Patients With Intellectual Disabilities of Genetic Origin
|
N/A | |
Terminated |
NCT05445596 -
Improving Treatment for Children With Intellectual and Developmental Disabilities and Problem Behavior in Schools
|
N/A | |
Recruiting |
NCT05131425 -
Facing Your Fears: Adolescents With ASD and Intellectual Disability
|
N/A | |
Completed |
NCT04436692 -
Dietary Intervention and Adults With Intellectual Disabilities
|
N/A | |
Completed |
NCT04917666 -
Process and Outcomes of Horticultural Therapy for People With Disabilities
|
N/A | |
Completed |
NCT04518358 -
Expert Guiding Technology to Help Individuals With Developmental Challenges Build Life and Vocational Skills
|
N/A | |
Completed |
NCT04554355 -
Effects of a PA Intervention for Fatness and Fitness in Adolescents With Intellectual Disability
|
N/A | |
Completed |
NCT04277130 -
Effectiveness of Active Video Games in Children With Intellectual Disabilities
|
N/A | |
Enrolling by invitation |
NCT02914951 -
Cognitive-Behavioral Therapy for Irritability in Children With Autism Spectrum Disorder and Intellectual Disability
|
N/A | |
Completed |
NCT02304302 -
Down Syndrome Memantine Follow-up Study
|
Phase 2 | |
Completed |
NCT03989388 -
Occupational Self-Analysis Programme
|
N/A |